In the aforementioned study by Mathey and colleagues, the authors noted that NF186 or gliomedin antibodies were not detected in the sera of their CIDP patient pool [96]. This evidence concerns the gene GLDN and chronic inflammatory demyelinating polyradiculoneuropathy.